Comparative Persistence With Biannual Prolia and Weekly Alendronate in post-menopausal women with osteoporosis living in one of 5 Asia-Pacific countries: a Prospective Observational Study.
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
- 16 Sep 2021 New trial record